Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Raloxifene (Celvista, Evista)].

J J Body1, J Sternon

  • 1Clinique des Soins Supportifs, Institut J. Bordet, U.L.B.

Revue Medicale De Bruxelles
|April 5, 2000
PubMed
Summary
This summary is machine-generated.

Selective Estrogen Receptor Modulators (SERMs) like raloxifene effectively prevent vertebral fractures in post-menopausal women. While not reducing hip fractures, raloxifene shows potential cardiovascular and breast cancer benefits, with a small risk of thromboembolic events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone strain index improves 10-year fracture risk prediction beyond bone mineral density and FRAX® in community-dwelling older women: A study of the FRISBEE cohort.

Bone·2026
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Selection for treatment of patients at high risk of fracture by the short versus long term prediction models - data from the Belgian FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohort.

Bone reports·2023
Same author

Are there specific clinical risk factors for the occurrence of multiple fractures? The FRISBEE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE Study.

Calcified tissue international·2022
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Bone Biology

Context:

  • Osteoporotic fractures pose a significant health risk for post-menopausal women.
  • Menopause management is crucial for preventing associated skeletal and other health issues.

Purpose:

  • To evaluate the efficacy and safety of raloxifene, a Selective Estrogen Receptor Modulator (SERM), in preventing osteoporotic fractures in post-menopausal women.
  • To assess raloxifene's impact on bone mass, vertebral and hip fracture incidence, cardiovascular risk factors, and breast cancer risk.

Summary:

  • Raloxifene, a second-generation SERM, increases bone mass by 1-3% and reduces vertebral fractures by 30-50% after 3 years of daily 60 mg therapy.
  • It is approved for preventing vertebral fractures in post-menopausal women at high risk, but has not demonstrated a significant reduction in hip fractures.

Related Experiment Videos

  • Adverse effects include a potential increase in thromboembolic disease risk (3.1-fold compared to placebo), though endometrial proliferation and vaginal bleeding are not increased.

    • Impact:

    • Raloxifene offers a non-estrogenic approach to managing osteoporosis and reducing vertebral fracture risk in post-menopausal women.
    • Further research is needed to confirm benefits on cardiovascular disease and breast cancer, and to compare long-term outcomes with estrogen replacement therapy.